Danaher Co. (NYSE:DHR) Shares Acquired by Dohj LLC

Dohj LLC raised its stake in shares of Danaher Co. (NYSE:DHR) by 105.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,345 shares of the conglomerate’s stock after acquiring an additional 1,715 shares during the quarter. Dohj LLC’s holdings in Danaher were worth $835,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its stake in Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after acquiring an additional 2,998,161 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Danaher by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after acquiring an additional 1,619,586 shares during the last quarter. Capital International Investors lifted its position in shares of Danaher by 9.1% in the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after buying an additional 1,334,781 shares during the last quarter. Norges Bank bought a new position in shares of Danaher in the 4th quarter worth about $1,752,382,000. Finally, Franklin Resources Inc. lifted its position in shares of Danaher by 6.4% in the 4th quarter. Franklin Resources Inc. now owns 6,620,170 shares of the conglomerate’s stock worth $1,531,510,000 after buying an additional 395,498 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the transaction, the chief executive officer now owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Matthew Mcgrew sold 46,377 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $7,441,441.35. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the sale, the chief executive officer now directly owns 106,990 shares in the company, valued at approximately $28,352,350. The disclosure for this sale can be found here. Insiders have sold a total of 148,783 shares of company stock valued at $37,536,717 over the last 90 days. 11.10% of the stock is currently owned by company insiders.

Danaher Price Performance

Shares of DHR traded up $0.18 during mid-day trading on Friday, hitting $251.94. The company’s stock had a trading volume of 990,305 shares, compared to its average volume of 2,820,554. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $269.11. The firm has a 50-day moving average price of $255.36 and a 200 day moving average price of $246.19. The stock has a market capitalization of $186.61 billion, a price-to-earnings ratio of 42.68, a PEG ratio of 3.88 and a beta of 0.85. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same period in the previous year, the company earned $2.36 earnings per share. The company’s revenue was down 2.6% compared to the same quarter last year. On average, research analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio is 18.31%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on DHR shares. Citigroup raised their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Robert W. Baird raised their price target on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Bank of America lifted their price objective on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and lifted their price objective for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Finally, Jefferies Financial Group started coverage on shares of Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $269.29.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.